Drugs / P3C541b
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000845 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00002353 | — | HIV infectious disease | United Biomedical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P3C541b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002353 ↗ |
| Modality | Vaccine | “HIV synthetic lipopeptide candidate vaccine component” NCT00000845 ↗ |
| Route | Subcutaneous | “administered subcutaneously (s.c.)” NCT00000845 ↗ |